Company Filing History:
Years Active: 2025
Title: Innovations by Stephen Kurtz in Acute Myeloid Leukemia Treatment
Introduction
Stephen Kurtz is an accomplished inventor based in Portland, OR (US). He has made significant contributions to the field of medical research, particularly in the treatment of acute myeloid leukemia (AML). With a total of 2 patents, his work focuses on novel therapeutic methods that address specific challenges in treating this aggressive form of cancer.
Latest Patents
Kurtz's latest patents include innovative methods for treating venetoclax-resistant acute myeloid leukemia. The first patent concerns novel treatment methods for patients with low expression of the TP53 protein or mutations in the TP53 gene. This invention involves administering a therapeutically effective amount of a NTRK/ALK/ROS1 inhibitor or a pharmaceutically acceptable salt thereof. The second patent relates to useful methods for treating AML in humans, particularly in the presence of gene mutations. These advancements represent a significant step forward in the fight against AML.
Career Highlights
Stephen Kurtz is affiliated with Oregon Health & Science University, where he conducts his research and develops his innovative treatments. His work has garnered attention for its potential to improve patient outcomes in those suffering from AML.
Collaborations
Kurtz collaborates with notable colleagues, including Jeffrey Tyner and Cristina Tognon. Their combined expertise enhances the research efforts aimed at finding effective treatments for acute myeloid leukemia.
Conclusion
Stephen Kurtz's contributions to the field of cancer treatment, particularly through his patents, highlight his commitment to advancing medical science. His innovative approaches offer hope for patients facing the challenges of acute myeloid leukemia.